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The HELLP syndrome is a pregnancy-associated disease inducing hemolysis, elevated liver enzymes, and low 
platelets in the mother. Although the HELLP symptoms occur in the third trimester in the mother, the origin 
of the disease can be found in the first trimester fetal placenta. A locus for the HELLP syndrome is present on 
chromosome 12q23 near PAH. Here, by multipoint nonparametric linkage, pedigree structure allele sharing, 
and haplotype association analysis of affected sisters and cousins, we demonstrate that the HELLP locus is in 
an intergenic region on 12q23.2 between PMCH and IGF1. We identified a novel long intergenic noncoding 
RNA (lincRNA) transcript of 205,012 bases with (peri)nuclear expression in the extravillous trophoblast using 
strand-specific RT-PCR complemented with RACE and FISH. siRNA-mediated knockdown followed by RNA-
sequencing, revealed that the HELLP lincRNA activated a large set of genes that are involved in the cell cycle. 
Furthermore, blocking potential mutation sites identified in HELLP families decreased the invasion capacity 
of extravillous trophoblasts. This is the first large noncoding gene to be linked to a Mendelian disorder with 
autosomal-recessive inheritance.
Introduction
Preeclampsia (new-onset hypertension in pregnancy with pro-
teinuria) and hemolysis, elevated liver enzymes, low platelets 
(HELLP) syndrome share a similar onset in the early placenta 
(1–3). Local placental dysfunction is followed by activation of 
compensatory pathways in the placenta (PlGF-sFLT1-endoglin 
axis) and mother (TGF-β–mediated NOS-dependent vasodila-
tion) that ultimately trigger the appearance of systemic mater-
nal symptoms (4–6). Genetically, the HELLP syndrome and 
preeclampsia are distinct entities (7). The familiar forms of 
preeclampsia involve the STOX1 gene (8). The HELLP gene is 
unknown, but 3 putative loci have been identified by genome-
wide linkage analysis (7). Given the consistent observation in 
monozygotic parous twins that lack of concordancy for pro-
teinuric hypertension is the rule rather than the exception, we 
searched these loci for the presence and identity of the HELLP 
gene, with the assumption that fetal (i.e., placental) contribu-
tions are essential for any genetic basis of HELLP (9).
Here we showed, by multipoint nonparametric linkage, pedi-
gree structure allele sharing, and haplotype association analysis 
of affected sisters and cousins, that the HELLP locus resides in 
an intergenic region on chromosome 12q23.2 between PMCH 
and IGF1. By strand-specific RT-PCR complemented with rapid 
amplification of cDNA ends (RACE) and FISH, a novel long 
intergenic noncoding RNA (lincRNA) transcript with expres-
sion in the placental extravillous trophoblast was identified. By 
siRNA-mediated knockdown followed by RNA sequencing, the 
HELLP lincRNA was found to be involved in the cell cycle. By 
using morpholinos to block potential mutation sites, as identi-
fied in HELLP families, we observed a decreased invasion capac-
ity of extravillous trophoblasts.
Results
Analysis of HELLP families reveals linkage to an intergenic region on 
12q23. Using the original cohort of families with the HELLP syn-
drome (n = 34; ref. 7), the 3 loci previously found to have nominal 
linkage were reanalyzed using additional microsatellite markers. 
The nonparametric lod scores for 12p12 and 20p12 decreased 
(from 1.55 to 1.08) and disappeared (from 1.70 to 0.37), respec-
tively. The lod score for the 12q23 region increased from nominal 
to suggestive (i.e., from 2.1 to 2.37).
We subsequently tested 57 individuals (7 families with affected 
sib-pairs, 4 families with affected cousin-pairs, and 2 discordant 
monozygous twin sisters with their partners, of which 36 females 
were affected) with 26 microsatellite markers (D12S309–D12S395) 
in the 23.6-Mb region on 12q23. Nonparametric multipoint link-
age analysis using Smnallele confirmed the 4-marker region between 
PAH and D12S1647 (lod and NPL scores >3; Figure 1A) and indi-
cated recessive inheritance (in descending order: Smnallele, Spairs, Sall, 
Srobdom; ref. 10). Pedigree analysis narrowed this region to 2 mini-
mal critical regions: D12S1607–PAH and D12S338–D123S317, 
each about 1 Mb. In the highly informative family 93113, in which 
2 sisters married 2 brothers from an unrelated family, maximal 
allele sharing in all affected females from 2 generations (cous-
ins and their mothers) was restricted to the first region near 
D12S1030 (Supplemental File 1; supplemental material available 
online with this article; doi:10.1172/JCI65171DS1).
We found no mutations in the coding sequences of the 38 
known and predicted genes within or near these 2 regions: 
DRAM, CCDC53, NUP37, C12orf48 (also referred to as PARPBP), 
PMCH, IGF1, PAH, ASCL1, C12orf42, BC041342, STAB2, NT5DC3, 
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Figure 1
Identification of the HELLP locus on chromosome 12q23.2. Multipoint nonparametric linkage analysis (A; see also Supplemental File 1), pedigree 
structure analysis with SNP/INDEL markers (B; see also Supplemental File 2), and HaploView analysis (C) defined the HELLP locus region as 
residing in a intergenic region of about 170 kb between C12orf48 and IGF1 on 12q23.2.
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LOC253724 (also referred to as GNN), HSP90B1, TDG, GLT8D2, 
HCFC2, NFYB, TXNRD1, EID3, CHST11, BC030271, SLC41A2, 
C12orf45, APPL2, OCC-1, RFX4, ACACB, FOXN4, UBE3B, ANAPC7, 
CCDC63, RPH3A, OAS1, P/OKCL.4, OAS2, DDX54, and LHX5. 
Instead, using the 181 SNPs and insertion/deletion polymor-
phisms (INDEL) identified, we found the HELLP locus to reside 
in an intergenic region of 154 kb (chromosome 12: 101,114,674–
101,268,434 bp; UCSC assembly NCBI36/hg18) between C12orf48 
and IGF1 (Figure 1B and Supplemental File 2).
We confirmed this region by haplotype association analysis 
(HaploView) following deep sequencing. We tested 26 singletons 
(sisters and cousins) with 405 SNP markers. We took advantage of 
the placental genotype-maternal phenotype discrepancy character-
istic for preeclampsia and HELLP (the maternal endophenotype is 
caused by the placental effector genotype, i.e., the genotype of the 
child born from the affected pregnancy), as this permitted case-
control association analysis within the family cohort. Phenotypi-
cally affected females born from phenotypically affected mothers 
were genetically considered cases, as the disease genotypes of the 
former are homozygous or compound heterozygous; phenotypi-
cally affected females born from nonaffected mothers were con-
sidered controls, as the former are unaffected, heterozygous carri-
ers. Using the “Solid Spine of LD” algorithm to evaluate blocks of 
linkage disequilibrium (LD) with a minimum D′ value of 0.8, the 
single block identified (chromosome 12: 101,150,849–101,320,921 
bp) confirmed that the HELLP gene was present within the inter-
genic region between C12orf48 and IGF1 on 12q23.2 (Figure 1C), a 
finding that was confirmed to be significant by permutation test-
ing (P = 0.0334; n = 5,000).
Discordant monozygotic twins confirm placental origin of the HELLP 
syndrome. In the discordant monozygotic twin sister family, the 
HELLP linkage region presented as a cluster of minor alleles 
with heterozygous sharing between the affected twin sister and 
her partner, while completely absent in the partner of the non-
affected twin sister. Using 3 informative SNPs in this cluster, 
we observed complete agreement with the placental model: the 
presence of a fetal susceptibility gene, expressed in placenta cells 
in contact with maternal vessels, determined the maternal phe-
notype (Figure 2).
The HELLP transcript is a lincRNA expressed in extravillous tro-
phoblasts. We screened the intergenic region for transcription 
in SGHPL-5, a diploid cell line representative of first-trimester 
extravillous trophoblast, the fetal cell central in the etiology of 
preeclampsia and HELLP (11). We performed a complete analysis 
of the number, size, 5′- and 3′-ends, splicing pattern, and cellu-
lar location of the transcript(s) involved. This identified a single, 
unspliced large transcript with 5′-cap structure and 3′-polyA-tail 
of 205,012 bases (chromosome 12: 101,115,493–101,320,504 bp; 
UCSC assembly hg18) with no coding potential (CPC, –0.874346; 
ref. 12 and Figure 3). By FISH, expression was found to be nucle-
ar, perinuclear, and cytoplasmic, both in vitro — in the extravil-
lous trophoblast cell line (SGHPL-5) used for its identification 
(Figure 4, A–C) — and in vivo (i.e., first trimester placenta tissue), 
whereas no signal was detected using a sense probe as negative 
control (Figure 4D). In the anchoring villi of human first-tri-
mester placenta tissue, (peri)nuclear expression was restricted to 
extravillous trophoblast cells and their precursors (i.e., column 
extravillous cytotrophoblasts; Figure 4E). In first-trimester pla-
centabed showing a front of extravillous trophoblast invasion 
into the myometrium, invasive extravillous trophoblast cells 
actively involved in maternal spiral artery modification showed 
a distinct difference in subcellular localization: predominantly 
nuclear in the endovascular trophoblasts within maternal spiral 
arteries, while perinuclear and cytoplasmic in the interstitial tro-
phoblast surrounding maternal spiral arteries (Figure 4, F and 
G). Comparison with the transcriptome assemblies of 17 adult 
Figure 2
Parent-child segregation of 12q23.2 region in monozygotic twin sisters discordant for HELLP. 3 informative SNPs located within the HELLP region 
with linkage were analyzed for parent-child segregation in discordant, monozygotic twin sisters. Only 1 sister (patient 1) developed the HELLP 
syndrome during pregnancy. The other sister (patient 3) had 2 normal pregnancies. The minor alleles (red) were homozygous in the child born of 
affected patient 1 (patient A). In contrast, homozygosity for the major alleles (green) was seen in the children born of normal patient 3 (patients 
B and C). This pattern supports the presence of a placental susceptibility gene for the HELLP syndrome, in which the fetal genotype expressed 
in the placenta determines the maternal phenotype.
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tissues (in addition to placenta) in the human lincRNA catalog 
(http://www.broadinstitute.org/genome_bio/human_lincrnas/) 
indicated that the HELLP lincRNA was preferentially, if not 
exclusively, expressed in the placenta (Supplemental File 3).
Genome-wide RNA sequencing indicates involvement in the cell cycle. 
Given its unknown function, its large size, and the absence of 
additional landmarks preventing prioritization of regions for 
functional and mutational analyses, we performed genome-wide 
Figure 3
Location of the HELLP lincRNA on chromosome 12q23, identified by overlapping strand-specific PCR amplifications supplemented by RACE 
experiments to identify the 5′ and 3′ ends.
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RNA-sequence (RNA-Seq) analysis after siRNA-mediated down-
regulation of the HELLP transcript in SGHPL-5 cells. The differ-
ential expression induced after HELLP transcript knockdown was 
analyzed using TopHat and Cufflinks software, calculating the 
significant differential expressions at the gene level. In this list, 3 
significant gene_id hits corresponded with downregulation of the 
HELLP transcript on chromosome 12q23. These hits had q values 
(P value corrected for false discovery rate [FDR]) of 0.019, 0.030, 
and 0.031 and showed expression values in the control sample of 
0.21, 0.12, and 0.15, respectively, whereas the siRNA-mediated 
knockdown sample value was 0 for all 3 hits. For subsequent vali-
dation analysis, the following selection criteria were used: q value 
threshold, <0.05; log2 fold change, ≥2; and a value of at least 1 of 
either the control sample or the siRNA-mediated knockdown 
sample. Furthermore, unannotated transcripts were excluded. 
By cross-checking the list of genes with the results obtained in 
an untransfected sample, the hits originating from transfection 
effects were omitted. This yielded 4 upregulated genes and 1,364 
downregulated genes upon knockdown of the HELLP transcript. 
Validation of the RNA-Seq results was performed by quantita-
tive RT-PCR assays on 14 transcripts, including all 4 upregulated 
genes, 5 downregulated genes with a q value of 0, a selection of 3 
genes with q values between 0 and 0.05, and a gene that did not get 
through the additional selection criteria (GRB10) as a negative con-
trol. One of the upregulated genes, AZIN1, consists of 2 transcripts 
of which only 1 is upregulated, while the other is downregulated 
but with a log2 fold change of –1.47; therefore, this gene also did 
not get through the additional selection criteria. Quantitative RT-
PCR (Supplemental File 4) showed that differential expression 
could be validated for genes with a q value below 0.01, with one 
exception; the upregulated gene MEG8 could not be validated with 
the opposite expression pattern observed likely to be caused and 
complicated by the 35 SNORD genes downstream of MEG8. The 
remaining transcripts — 1 with upregulated expression and 8 with 
Figure 4
Localization of the HELLP lincRNA. FISH showed nuclear (A), perinuclear (B), and cytoplasmic (C) localization in SGHPL-5 cells; (D) no signals 
were seen using a sense probe as negative control. (E) In first-trimester placental tissue, nuclear and perinuclear expression was found in the 
anchoring villous, consisting of column extravillous trophoblasts and villous cytotrophoblasts. (F) In first-trimester placentabed, localization was 
found to be nuclear in endovascular extravillous trophoblasts (arrows), whereas interstitial trophoblasts showed predominant perinuclear and cyto-
plasmic expression (arrowheads). (G) First-trimester placentabed showing the front (dotted line) of the extravillous trophoblast invasion into the 
myometrium. Inset: nuclear endovascular expression of the HELLP lincRNA (enlarged ×4.5). Scale bars: 5 μm (A–D); 30 μm (E and F); 100 μm (G).
Table 1
Top 10 networks from ingenuity pathway analysis
Network ScoreA Focus genesB
Cellular function and maintenance, cell morphology, nervous system development and function 34 32
Cell cycle, DNA replication, recombination, and repair, cellular assembly and organization 32 31
Gene expression, DNA replication, recombination, and repair, cell cycle 30 30
Cancer, cellular development, cellular growth and proliferation 28 29
Cell cycle, DNA replication, recombination, and repair, cellular assembly and organization 27 28
Cell death, liver necrosis/cell death, molecular transport 25 27
Cellular movement, cardiovascular system development and function, cellular assembly and organization 22 25
Antigen presentation, cell-to-cell signaling and interaction, hematological system development and function 20 24
Cell morphology, embryonic development, organ development 15 20
RNA damage and repair, molecular transport, RNA trafficking 15 20
ASignificance score of the network, shown as the negative log of the P value. The score indicates the significance of the assembly of the set of focus genes 
in the network. BNumber of genes from the submitted gene list that are present in the network.
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downregulated expression after siRNA-mediated knockdown — 
could be validated. The gene list selected with the criteria used for 
validation analysis was accordingly adjusted to a q value threshold 
of <0.01. This validated set, excluding MEG8, consisted of 1,198 
upregulated genes and 1 downregulated gene (Supplemental File 
5) and was submitted to Ingenuity Pathway Analysis (IPA; see 
Methods). The top 10 networks from network analysis showed 
they were predominantly associated with the cell cycle (Table 1). 
Furthermore, function annotation analysis revealed significant 
increases in functions related to G1/S phase and cell death, whereas 
significant decreases were found for functions related to G2/M 
phase, cell survival, and migration (Supplemental File 6).
Blocking potential mutation sites decreases extravillous trophoblast 
invasion. Although we have not yet identified all disease-causing 
mutations in the complete set of HELLP families, we identified 
a couple that segregate correctly with the disease phenotype in 
all generations with compound heterozygosity in the patients 
involved. These sequence variants, RW18-5 (C→T at position 
101,120,459), HAPLO378 (A→G at position 101,319,702), 
and HAPLO215Rev (G→C at position 101,241,930), were not 
found in 200 control chromosomes of nonaffected individu-
als of similar race and therefore qualified as mutations (Figure 
5A). Functional studies were performed using morpholinos 
to block the regions containing these sites. Validation of their 
experimental effect showed that blocking the different mutation 
sites using optimal morpholino concentrations (5 μM) seem to 
prevent HELLP lincRNA degradation, leading to a net increase 
in HELLP lincRNA levels (Figure 5B). Using the combination 
of HAPLO378 with HAPLO215Rev morpholinos (being com-
pound heterozygotes in family 9265) with a concentration of 2.5 
μM each did not show this effect as clearly. Single morpholinos 
at a concentration of 2.5 μM could also not show this increase 
in HELLP lincRNA levels (data not shown). If these sites are of 
functional importance and critical in the pathophysiology of the 
HELLP syndrome, the morpholino blocking effects should (a) 
be seen in trophoblast cells; (b) affect the expression of the same 
genes as identified by RNA-Seq, but in the opposite direction, as 
blocking shows an upregulation of the HELLP lincRNA instead 
of siRNA-mediated knockdown; (c) exhibit a greater effect when 
the mutations that segregate in the same patient are tested in 
combination. Finally, the transcriptional effects should be fol-
lowed by a functional cellular effect, i.e., defective trophoblast 
invasion. This was exactly the situation observed when using 
the different morpholinos separately or in combination. The 
increase in HELLP lincRNA was followed by increased transcript 
levels of downstream effector genes when using the RW18-5 or 
HAPLO215Rev morpholino, while this was not observed for 
HAPLO378 (Figure 5C). In addition, while the individual effects 
of suboptimal doses (2.5 μM) of the morpholinos when tested 
separately were incomplete (data not shown), the effect was 
complete when HAPLO378 and HAPLO215Rev were tested in 
combination. Finally, we performed Matrigel invasion assays in 
the SGHPL-5 cells to test whether these transcriptional changes 
are accompanied by a phenotypic effect mimicking the primary 
clinical defect (i.e., decrease in trophoblast invasion). The results 
confirmed our findings: HAPLO378 did not have an effect on 
invasion, whereas RW18-5 significantly decreased the number of 
invaded cells, as did HAPLO378 and HAPLO215Rev in combina-
tion at 2.5 μM each. Furthermore, HAPLO215Rev showed a clear 
trend toward a decrease in invaded cells (P = 0.0645; Figure 5D).
Discussion
Here we show by multipoint nonparametric linkage, pedigree struc-
ture allele sharing, and haplotype association analysis of HELLP-
affected sisters and cousins that the locus of the HELLP syndrome 
resides in an intergenic region on chromosome 12q23.2 between 
PMCH and IGF1. By strand-specific RT-PCR complemented with 
RACE experiments, we identified an unspliced noncoding RNA 
transcript of 205 kb in length located within this intergenic region. 
The transcript was furthermore found to be expressed in extravil-
lous trophoblasts. In first-trimester placenta, the expression was 
predominantly nuclear in the endovascular extravillous tropho-
blasts, while interstitial extravillous trophoblasts mainly showed 
perinuclear and cytoplasmic expression. Results of whole-genome 
RNA-Seq indicated that the HELLP lincRNA is involved in 1 or 
more processes in the cell cycle, in which siRNA-mediated knock-
down of the transcript leads to reduced activity of the G2/M phase 
of the cell cycle, while the G1/S phase shows an increase in activity.
By using morpholinos to block potential mutation sites as iden-
tified in HELLP families, we found that they were able to upregu-
late the expression of the HELLP lincRNA. This suggests that the 
morpholinos are blocking the breakdown of the transcript itself. 
Consistent with upregulated expression of the lincRNA, both the 
RW18-5 and especially the HAPLO215Rev morpholino were able to 
upregulate downstream effector genes found to be downregulated 
upon siRNA-mediated knockdown of the transcript. The combina-
tion of HAPLO378 and HAPLO215Rev morpholinos, as found in 
one of the HELLP families, showed similar effects. Finally, by using 
invasion assays, we found that morpholino RW18-5 and the combi-
nation of HAPLO378 with HAPLO215Rev significantly decreased 
the amount of invaded extravillous trophoblast cells, whereas HAP-
LO215Rev showed a trend toward a reduction in extravillous troph-
oblast invasion. This would fit the placental origin of the HELLP 
syndrome, in which extravillous trophoblasts show reduced inva-
sion into the maternal decidua, caused by reduced differentiation 
of the extravillous trophoblasts from a proliferative toward an inva-
sive phenotype. This concept was already indicated by the RNA-Seq 
results showing effects on the cell cycle, in which siRNA-mediated 
knockdown of the HELLP lincRNA led to decreased activity of the 
G2/M phase, whereas the G1/S phase showed increased activity.
In summary, we showed a region on chromosome 12q23 to be 
associated with the HELLP syndrome by genome-wide linkage anal-
ysis of families with the disease. The region contains a noncoding 
RNA transcript more than 205 kb in length. This lincRNA was local-
ized in early placenta extravillous trophoblasts and, by genome-wide 
RNA analysis followed by pathway analysis, found to classify as an 
activator affecting a large set of genes involved in the cell cycle, in 
particular in activating the G2/M phase while deactivating the G1/S 
phase. Blocking potential mutation sites as identified in HELLP fam-
ilies decreased the invasion capacity of extravillous trophoblasts, con-
sistent with the placental origin of the HELLP syndrome. lincRNAs 
have so far been implicated in chromatin remodeling, transcriptional 
control, and post-transcriptional processing (13–15). The next step is 
to identify the precise function of this lincRNA as a regulating non-
coding RNA and its dysfunction in the HELLP syndrome.
Methods
Patient recruitment. In our genetic studies, we included all HELLP families 
available to us that included at least 2 affected females (sisters or cousins). 
The original cohort of families (n = 67) with preeclampsia, eclampsia, the 
HELLP syndrome, or pregnancy-induced hypertension (PIH), recruited 
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Figure 5
Blocking potential mutation sites 
decreases extravillous trophoblast 
invasion. (A) 3 potential mutations were 
investigated in detail. RW18-5 (C→T at 
position 101,120,459) occurred in family 
9401; the mutation on the other allele 
has not yet been identified. HAPLO378 
(A→G at position 101,319,702) and 
HAPLO215Rev (G→C at position 
101,241,930) occurred as compound 
heterozygous mutations in family 9265. 
HAPLO378 was also present in fam-
ily 93113. Women affected by HELLP 
are indicated by black symbols; chil-
dren born of HELLP pregnancies are 
indicated by gray symbols. Potential 
mutagenic alleles are also shaded gray. 
(B) Morpholinos at a concentration of 
5 μM blocking the potential mutagenic 
sites upregulated expression of the 
HELLP lincRNA in SGHPL-5 cells. (C) 
Upregulation of the HELLP lincRNA led 
to upregulation of downstream effec-
tor genes that showed downregulation 
after siRNA-mediated knockdown of the 
transcript when the RW18-5 or HAP-
LO215Rev morpholino was used at a 
concentration of 5 μM. The combination 
of HAPLO378 and HAPLO215Rev (2.5 
μM each) also upregulated the down-
stream effector genes. (D) Invasion of 
SGHPL-5 cells significantly decreased 
when RW18-5 morpholinos were intro-
duced, whereas HAPLO215Rev trend-
ed toward a significant decrease in inva-
sion. HAPLO378 did not affect invasion. 
The combination of HAPLO215Rev and 
HAPLO378 (2.5 μM each) significantly 
decreased the amount of invaded cells. 
*P < 0.05; **P < 0.01.
research article
4010 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 11   November 2012
don, London, United Kingdom), RNA was isolated using the RNeasy mini 
kit (Qiagen) including on-column DNase treatment, and reverse tran-
scription was performed using the SuperScript III First-Strand Synthesis 
System for RT-PCR (Invitrogen) using random hexamers as well as gene-
specific reverse primers to confirm strand specificity. Overlapping PCRs 
covering the complete area between the genes PMCH and IGF1 was per-
formed on cDNA using Platinum Taq DNA Polymerase High Fidelity (Inv-
itrogen). To cover the complete transcript, 42 PCRs were needed yielding 
2- to 7-kb PCR products. Confirmation of the correct products amplified 
was done by sequencing using BigDye Terminators and analyzed on an 
ABI3130XL genetic analyzer (Applied Biosystems). On the 5′ and 3′ ends 
of the transcript, where PCR products could no longer be amplified, 5′and 
3′ RACE experiments were performed using the Generacer kit according to 
the manufacturer’s instructions (Invitrogen). The exact transcript bound-
aries were confirmed by sequencing. See Supplemental File 7 for primer 
sequences. The HELLP transcript sequence described herein was deposited 
in GenBank (accession no. JX088243).
Placental tissue collection. First-trimester placentas were obtained at the 
time of elective termination of pregnancy. Informed consent was obtained 
from each patient, and collections were approved by the Ethical Commit-
tee of the VU University Medical Center and the Flevoziekenhuis Almere. 
Tissue was collected into ice-cold PBS. After extensive washing the placen-
tal tissues were submerged in Tissue-Tek and plated at –80°C.
FISH. RNA FISH was carried out on SGHPL-5 cells and 5-μm-thin pla-
cental tissue cryostat sections, using oligonucleotide probes (Supplemen-
tal File 7) against the HELLP lincRNA labeled with digoxigenin (DIG) at 
the 5′ and 3′ end (Eurogentec), as described previously (20). Briefly, after 
fixation, slides were prehybridized for 30 minutes at 41°C (25°C below 
the Tm of the probe) in a humidified chamber with prehybridization buf-
fer, then incubated with hybridization buffer containing an antisense or a 
sense probe with final concentrations of 100 ng/ml for 1 hour. Posthybrid-
ization washes with SSC buffer were done at 5°C higher than the hybrid-
ization temperature. Slides were incubated in blocking buffer (Roche) for 
30 minutes, followed by anti-DIG/HRP antibody (Roche) preabsorbed at 
1:500 dilution for another 30 minutes in a humidified chamber at room 
temperature. The signals were amplified using tyramide signal amplifi-
cation (TSA, 1:50 dilution; PerkinElmer) for 5 minutes in a humidified 
chamber. Slides were dehydrated in ethanol and mounted in Vectashield 
containing DAPI nuclear stain (Vector Laboratories). Visualization was 
performed on a Leica DM5000B microscope.
siRNA-mediated knockdown. The SGHPL-5 cell line was transfected with 
either scrambled siRNA or a combination of 4 siRNAs against the lincRNA 
evenly spread across the transcript (Supplemental File 7), using Lipofectamine 
RNAiMAX according to the manufacturer’s instructions (Invitrogen). siRNA 
knockdown was assessed by quantitative RT-PCR on RNA from transfected 
cells using primers and a probe (Supplemental File 7) specific for the tran-
script using the Taqman EZ RT-PCR kit (Applied Biosystems). The log2 fold 
change knockdown value was at least –5 in all transfections used.
RNA-Seq and pathway analysis after siRNA-mediated downregulation. RNA-Seq 
was performed on 1 untransfected sample and 2 independent transfection 
couples consisting of a scrambled control sample and an siRNA-mediated 
knockdown sample as described above. Total RNA (1 μg/sample, DNase-treat-
ed, RIN ≥9.8) was subjected to a double round of poly-A mRNA purification, 
fragmented, and primed for cDNA library synthesis using the TruSeq RNA 
sample preparation kit (FC-122-1001). All procedures were done according to 
the manufacturer’s instructions (Illumina). Following validation (Agilent 2100 
Bioanalyzer, DNA High Sensitivity) and normalization (AUC 200- to 500-bp 
fragments), samples were clustered (TruSeq paired-end cluster kit v3-cBot-
HS, PE-401-3001) followed by paired-end sequencing (100 bp; TruSeq SBS 
kit v3-HS 200 cycles, FC-401-3001) on a HiSeq2000. To maximize coverage 
from 22 hospitals in the Netherlands and used for genome-wide linkage 
analysis, has been described elsewhere (7). We collected blood samples with 
informed consent of all affected females and their parents, when available. 
We collected blood samples from a monozygotic twin sister pair and their 
partners. The twin sister pair was discordant for the HELLP syndrome: 
only one developed the disease during pregnancy. The nonaffected twin 
sister had two normal pregnancies. We collected buccal swabs from all chil-
dren available to us born from affected pregnancies and, if available, from 
nonaffected pregnancies from the same families.
In order for a family to be included, the clinical profiles of the affected 
females had to meet the strict criteria: (a) LDH ≥600 IU/l, ASAT ≥70 IU/l, ALAT 
≥70 IU/l, and ≤100 platelets × 109/l; (b) at least 2 affected females in each family 
(single exception: monozygotic twin sisters); and (c) DNA available from at 
least 2 generations. For most families, DNA was available from 3 generations. 
All families were of mixed European descent, with no apparent relationship 
among families except for family 93113, in which 2 brothers married 2 sisters 
from an unrelated family. The daughters born from these couples both devel-
oped HELLP. These double–first cousins were informative for the fact that 
the IBD alleles shared were maximal within the minimal critical region. Ethics 
committee approval was secured from all participating hospitals. All of the 
participants or their legal representatives gave informed consent.
Multipoint linkage analysis with microsatellite markers. We performed nonpara-
metric allele-sharing linkage analysis with 26 microsatellite markers located 
on 12q23 between D12S309 and D12S395 on 53 individuals (35 affected 
females). The marker alleles in individual samples were analyzed by PCR with 
oligonucleotide primers labeled with 6-FAM or HEX. PCR product lengths 
were determined by capillary electrophoresis using ABI3100 or ABI3130XL 
genetic analyzer (Applied Biosystems) and analyzed using GeneScan or Gen-
emapper (version 4.0; Applied Biosystems). DNA from Centre d’Etude du 
Polymorphisme Humain (CEPH) individual 1347/02 was considered the 
standard for DNA fragment lengths. Nonparametric lod scores were calcu-
lated using Allegro version 2 (16). Allele frequencies were obtained from the 
CEPH genotype database (version 10.0; www.cephb.fr). The order and posi-
tion of the markers were derived from the Decode genetic map (17). Marker, 
linkage, and family data are shown in Supplemental File 1.
Identity-by-descent allele-sharing analysis with SNPs and INDEL polymorphism 
markers. We designed primers using Primer 3 (http://frodo.wi.mit.edu) or 
ExonPrimer (http://ihg.gsf.de/ihg/ExonPrimer.html) to amplify exons of 
the 38 known and predicted genes in the regions with linkage. We analyzed 
exon fragments by cycle sequencing on an ABI3130XL Genetic Analyzer 
(Applied Biosystems). We analyzed the data by Sequencing Analysis (ver-
sion 3.7; Applied Biosystems) or 4Peaks software (http://www.mekentosj.
com/science/4peaks). The SNPs and INDEL polymorphisms we identified 
were used for pedigree structure analysis of the regions with nonparamet-
ric lod scores >3 (Supplemental File 2).
Haplotype block analysis. Tag SNPs were designed with Tagger (18) and 
sequenced as described above. See Supplemental File 7 for primer sequenc-
es. Case-control association analysis was performed for the familial cohort 
studied. Affected females born from affected mothers were considered cases 
(homozygous or compound heterozygous patients); affected females born 
from nonaffected mothers were considered controls (heterozygous carriers). 
We tested 26 singletons (sisters and cousins) with 405 SNP markers. We 
used Haploview version 4.2 (19) to evaluate blocks of LD using the “Solid 
Spine of LD” algorithm with a minimum D′ value of 0.8. The Solid Spine 
of LD method internal to Haploview defines a block when the first and last 
markers are in strong LD with all intermediate markers. Marker settings 
were as follows: HW P value, cutoff 1.0; minimum percentage genotype, 
100; maximum number Mendelian errors, 1; minor allele frequency, 0.05.
Detailed transcript analysis. From the extravillous trophoblast cell line 
SGHPL-5 (11), provided by J. Cartwright (St. George’s University of Lon-
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facturer’s instructions. Efficient morpholino delivery was monitored using a 
fluorescein-labeled control. Cytotoxicity was observed at morpholino concen-
trations greater than 5 μM. RNA was isolated after 48 hours, followed by quan-
titative RT-PCR experiments for the HELLP lincRNA, HMMR, USP1, NUF2, 
ERBB2IP, C12orf48, SMC2, RECQL, and MRE11A and normalized for GAPDH, 
all as described above. Data were obtained from 3 independent experiments. 
In the invasion assays, morpholinos were delivered in serum-starved SGHPL-5 
cells using EndoPorter. 50,000 cells were plated on 100 μl diluted Matrigel-
coated (BD) 8.0-μm cell culture inserts, and the cells invaded for 48 hours. 
The insert membranes were fixed, covered in Vectashield with DAPI (Vector 
Laboratories), and coverslipped, after which the whole underside membrane 
was counted. Data were obtained from 6 independent experiments.
Statistics. Unless otherwise indicated, statistical analyses were performed 
using Graphpad Prism software and a 1-sample t test with theoretical mean 
of 0. P values less than 0.05 were considered significant. Results are pre-
sented as mean ± SEM.
Study approval. The studies performed on human samples were approved 
by the Ethical Committee of the VU University Medical Center and, in the 
case of placental tissues, also by the Ethical Committee of the Flevozieken-
huis Almere. Informed consent was obtained from all patients.
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with inclusion of low-abundance transcripts (21, 22), each lane contained a 
single DNA library. Cluster densities were 623–970 K/mm2, q scores (≥Q30) 
43.2%–80.5%, and FastQ output 44.44–69.17 gigabase for both forward and 
reverse reads. RNA-Seq reads were aligned to the preassembled reference 
genome (Illumina iGenome, data source UCSC assembly hg18; June 20, 2011) 
using Tophat (version 1.4.0) in combination with Bowtie (version 0.12.5) and 
SAMtools (version 0.1.18) using the default settings (23). Transcript assembly, 
abundance estimation (defined as fragments per kilobase of exon per mil-
lion fragments mapped; FPKM), and differential expression was performed 
by sequential analysis of Tophat output (accepted_hits.bam). For this, tran-
scripts were assembled using Cufflinks (version 1.3.0) under conditions (RABT 
assembly; ref. 24) permitting the identification of novel unannotated tran-
scripts (transcripts.gtf) and with correction for fragment bias to account for 
biases in library preparation (25). The assemblies to be compared were merged 
(Cuffmerge), generating a transcript index (merged.gtf). Subsequently, dif-
ferential analysis of significant changes in transcript expression, splicing and 
promoter use was performed (Cuffdiff) in the different transfection couples 
(scrambled vs. siRNA-mediated knockdown). All transfected samples were 
also compared with the untransfected sample. These data were checked for the 
occurrence of the HELLP lincRNA and downregulation of this transcript in 
the siRNA-mediated knockdown samples. The transfection couple of scram-
bled and siRNA-mediated knockdown samples with the highest difference 
was used in subsequent validation and pathway analysis in combination with 
the analyses with the untransfected sample to remove transfection-induced 
effects. Genes with significant differential expression were sorted by q value (P 
value corrected for FDR) and log2 (fold change). IPA (build 140500; Ingenu-
ity Systems Inc.) was performed on the gene list with differentially expressed 
genes, including the additional selection criteria described above.
Validation experiments by quantitative RT-PCR. Quantitative RT-PCR 
using gene expression assays (Applied Biosystems) for MEG8, GRB10, 
HMMR, USP1, NUF2, ERBB2IP, C12orf48, SMC2, RECQL, MRE11A, CRYAB, 
LOC388564, AZIN1 (transcript 1), and AZIN1 (transcript 2) were per-
formed on an ABI7300. Normalization was done with gene expression 
assays for GAPDH.
Morpholino-mediated transcript block and Matrigel invasion assays. Morpholinos 
blocking 3 different potential mutation sites (Supplemental File 7) and the 
standard negative control morpholino (Gene Tools) were delivered into the 
SGHPL-5 cell line using EndoPorter (Gene Tools) according to the manu-
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